Five Prime Therapeutics

$3.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-2.40%) Today
$0.00 (0.00%) As of 4:00 PM EST after-hours

Why Robinhood?

You can buy or sell FPRX and other stocks, options, ETFs, and crypto commission-free!

About FPRX

Five Prime Therapeutics, Inc. Common Stock, also called Five Prime Therapeutics, is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. Read More The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Employees
209
Headquarters
South San Francisco, California
Founded
2001
Market Cap
133.19M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
382.90K
High Today
$3.78
Low Today
$3.62
Open Price
$3.75
Volume
207.21K
52 Week High
$13.97
52 Week Low
$3.22

Collections

FPRX News

ReutersNov 12

Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT

Q3 2019 Five Prime Therapeutics Inc Earnings Call San Francisco Nov 12, 2019 (Thomson StreetEvents) -- Edited Transcript of Five Prime Therapeutics Inc earning
1

FPRX Earnings

-$1.37
-$1.10
-$0.82
-$0.55
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
-$0.95 per share
Actual
-$1.03 per share

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.